

## **Caris Diagnostics Announces Name Change to Miraca Life Sciences**

*Company to Provide Same High-Quality Anatomic Pathology Services Under New Name*

Tokyo, Japan & Irving, Texas, February 3, 2012 -- Caris Diagnostics, specializing in academic-caliber anatomic pathology services, today announced a company name change to Miraca Life Sciences, Inc., following its November 2011 acquisition by Tokyo-based Miraca Holdings Inc., Japan's largest clinical diagnostics and laboratory testing service provider. The name change, which is effective February 20, 2012, follows a successful integration process and will be reflected in all marketing and communications.

"The new name is a logical step as we complete the successful ownership transition of this world-class diagnostics organization," said Takeo Hayashi, Chairman and CEO of the newly-named Miraca Life Sciences. "While the name has changed, the fundamental value proposition has not: a unique, high quality pathology practice with an abiding commitment to diagnostic excellence and improved patient care."

Since 2005, Caris Diagnostics has established an unprecedented reputation among clinicians by creating an innovative, best-in-class practice that results in improved patient care. The word "Miraca" is a combination of the Japanese words 'future' and 'science', so the new corporate name is a natural fit for the company's mission and Miraca's global network of employees, clinicians and patients.

### **About Miraca Life Sciences**

Miraca Life Sciences specializes in the development and commercialization of the highest quality anatomic pathology services, primarily in the fields of dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company's core team of more than 70 world-leading, academic-caliber specialists utilize state of the art pathology laboratories currently headquartered in Irving, TX and throughout the United States to serve more than 3,000 patients every day. Through rigorous quality assurance, daily and monthly conferences, and close relationships with clinical partners, Miraca Life Sciences continuously improves diagnostic precision.

### **About Miraca Holdings**

With group net sales of ¥165.7 billion (FYE 3/2010), Miraca Holdings, a Japan-based holding company in the healthcare sector listed on the Tokyo Stock Exchange, is engaged in the business consisting of three segments: (i) development, manufacture, and commercialization of in vitro diagnostics, (ii) clinical laboratory testing, and (iii) other healthcare related businesses, which are conducted by its subsidiaries and affiliates including Fujirebio Inc., a leading supplier of in vitro diagnostics in Japan, and SRL, Inc. ("SRL"), Japan's largest commercial laboratory. SRL offers comprehensive clinical laboratory testing services to medical institutes throughout the nation, ranging from general testing to esoteric testing, including gene-based tests.

### **Media Contact:**

Perry Street Communications

Jeana Foxman

214-965-9955

jfoxman@perryst.com